Here’s what you need to know.
1. The company plans to launch its product across the European Union in the coming year.
2. The test is marketed as having “the potential to reduce colonoscopies by up to 25 percent while maintaining almost 97 percent detection of colorectal cancer when combined with the fecal immunochemical test score.”
3. The test is the first VolitionRx plans to bring to market.
More articles on gastroenterology/endoscopy:
Dr. Theresa Ruddy joins Oswego Health: 4 notes
5 most read GI/endoscopy stories — Dec. 26 to Dec. 30, 2016
GI leader to know: Dr. Michael Brody of Cary Gastroenterology Associates
